RVTY · Revvity, Inc.

The thesis

Revvity's case still rests on artificial intelligence (AI) drug-discovery customers turning the company's strongest instrument backlog in three to four years into Life Sciences revenue growth. The third-quarter 2026 report, due before the market opens on 3 November 2026, settles it. Life Sciences has to return to positive organic growth, and the 4–5% fiscal 2026 organic-growth outlook has to hold.

The shares have moved further ahead of that test. They closed at $161.86 on 27 October 2026, a 52-week closing high, up from $152.12 on 14 October 2026, according to adjusted daily closes. That puts the three-month gain at 42.6%. MarketBeat's 27 October 2026 count shows 18 firms with a consensus price target of $124.43, and 13 of them rate the shares Hold.

Since the 15 October 2026 note, the new information has come from peers. Revvity has published no financial figures since its 4 August 2026 second-quarter release. On 21 October 2026 Danaher reported third-quarter core revenue growth of 3.0%, or 5.5% excluding respiratory testing, and raised its 2026 adjusted earnings per share (EPS) guidance to $8.57–$8.62. Thermo Fisher's October third-quarter report showed 6% organic growth and a raised outlook, according to 24/7 Wall St.

Firmer peer demand supports a Life Sciences recovery, but the share price already assumes a strong quarter. The narrative is maturing: the backlog story has been public since the 4 August 2026 call, and fresh attention since then has come from broker target increases, most recently TD Cowen's on 13 October 2026. On that evidence, the shares are judged slightly less likely than not to beat the S&P 500 over the next three months.

Bullish and bearish views on Revvity, Inc.

The bull case on Revvity, Inc. (RVTY), in brief: Instrument orders exceed production capacity. The bear case: Life Sciences is still shrinking.

Bull case

• Instrument orders exceed production capacity. On the 4 August 2026 call, management said orders for the Opera Phenix OptIQ high-content screening system were arriving faster than it could build them. It tied the backlog to AI-driven drug-discovery customers.
• Broker targets are still rising. TD Cowen kept a Buy rating and raised its target to $175 from $130 on 13 October 2026 (Benzinga). In October 2026, Baird raised its target to $164 from $144 (MarketScreener).
• A new broker frames the AI demand. William Blair initiated at Outperform on 5 October 2026. It argued that AI-designed drug candidates need new wet-lab data and automated lab equipment (Investing.com), and it models 4.8% organic growth for 2026.
• Peers raised guidance in October. Danaher lifted its 2026 adjusted EPS guidance to $8.57–$8.62 from $8.45–$8.60 on 21 October 2026. Its CEO described improving trends across its end markets.
• Guidance was raised in August. On 4 August 2026 Revvity lifted fiscal 2026 pro forma organic growth to 4–5% from 3–4%. It set adjusted EPS at $5.30–$5.40 and revenue at $2.83–$2.86 billion.
• Diagnostics carries the group. Second-quarter Diagnostics revenue was $371 million, up 11% on a pro forma organic measure, according to the 4 August 2026 release.

Bear case

• Life Sciences is still shrinking. Second-quarter Life Sciences revenue was $359 million, down 3% on a pro forma organic measure, per the 4 August 2026 release. The backlog has yet to appear as segment growth.
• The price is far above consensus. MarketBeat's 27 October 2026 consensus target is $124.43. RBC Capital's target is $135 (set 1 September 2026) and UBS's is $140 (set 9 September 2026), both with neutral ratings.
• The valuation is rich. MarketBeat listed a trailing price-to-earnings ratio of 76.39 and a market value of $17.90 billion on 27 October 2026.
• AI also threatens part of the business. William Blair's 5 October 2026 initiation expects AI-led drug discovery to pressure Revvity's high-throughput screening business, though it judges the gains in instruments and reagents to be larger.
• Insiders sold in September. SEC Form 4 filings, via MarketBeat, show Tajinder Vohra sold 7,330 shares at an average $140.88 on 16 September 2026, about 52% of his holding.
• Rates are a headwind for richly valued tools stocks. The Federal Reserve raised rates the week of 18 September 2026, and the 10-year Treasury yield touched 5.04%, a 2007 high (Benzinga).

Price setup

The 27 October 2026 close of $161.86 is the 52-week closing high in adjusted daily closes. The 14-day relative strength index (RSI) is 66.2, just under the 70 level often read as overbought. MarketBeat put the 50-day moving average at $140.14 and the 200-day moving average at $110.69 on 27 October 2026, so the shares trade well above both rising averages.

Several crowding signs are visible. The shares are stretched above the 50-day average, the quarterly report is four sessions away, and the most recent insider transactions are September sales. Company news over the past month consists of broker actions, a product launch and automated return articles, with no sign of heavy retail attention. No share issuance appears in recent filings.

The first reference level below the price is the $152.12 close on 14 October 2026. The $140 area comes next, where the 50-day average and the UBS target meet. A drop back to $140 would undo the run-up that followed the August guidance raise.

Catalysts, next 30 days

• 3 November 2026: Third-quarter 2026 results before the open; call at 7:30 a.m. ET. A 7 October 2026 Barchart preview on Yahoo Finance put consensus EPS at $1.28, against $1.18 a year earlier, and full-year consensus at $5.36. The report decides the case through Life Sciences organic growth, backlog conversion and the 4–5% outlook.
• 13 November 2026: $0.07 quarterly dividend payable to holders of record on 23 October 2026. This is routine and does not bear on the case.
• ~31 December 2026 (est.): Expected closing of the Human Cell Design acquisition. It adds metabolic-disease research tools. Revvity has not disclosed a revenue contribution.

What would change the view

The case breaks if Life Sciences organic growth is still negative in the 3 November 2026 report, or if the 4–5% fiscal 2026 organic-growth outlook is cut. It also breaks if management describes the instrument backlog as timing of orders rather than a lasting step-up in AI-driven demand. In price terms, a weekly close below $140 would put the shares back at the 50-day moving average and the UBS target.

The read would improve with positive Life Sciences organic growth, a raised full-year outlook and backlog converting into shipments. Broad target increases from the neutral-rated brokers would also help, since the share price now sits well above the $124.43 consensus.

What it trades with

Revvity trades with the life-science tools group, which includes Thermo Fisher, Danaher and Agilent. Danaher's and Thermo Fisher's October guidance raises have moved sentiment for the whole group. The shares also respond to news about AI drug discovery, through the Opera Phenix backlog.

The group is sensitive to rates. The 10-year Treasury yield touched 5.04% the week of 18 September 2026. The Diagnostics half of the business follows reproductive-health and newborn-screening volumes more than drug-discovery spending. The pending sale of the China immunodiagnostics business will reduce exposure to China once it closes, which is expected by the end of 2027.